a biotech self-correction is in store, says oppenheimer's jared holz
Published 2 years ago • 8.9K plays • Length 7:09
Download video MP4
Download video MP3
Similar videos
-
3:43
the direction of m&a in biotech is very, very vast, says oppenheimer's holz
-
4:53
here's who could benefit from biden's biotech initiative, according to oppenheimer's jared holz
-
5:41
mizuho's jared holz on what trump's fda pick means for biotech innovation
-
12:12
jim bianco joins schwab network to explain why the fed should not cut rates anymore
-
3:33
pfizer pill approval news already priced into stock: oppenheimer's jared holz
-
3:10
i don't see a market catalyst right now, says ab's jim tierney
-
9:28
goldman sachs' jared cohen on powering the ai revolution: the u.s. won't be able to lead on its own
-
4:11
'godfather of ai' warns that ai may figure out how to kill people
-
6:50
3-stock lunch: alphabet, target, & eqt corp.
-
2:42
oppenheimer's stoltzfus sees a healthy rotation trade
-
6:46
pharma will move higher, but oppenheimer's holz is hesitant on valuations
-
4:42
'overuse' is causing healthcare insurer headwinds, says mizuho's jared holz
-
4:31
blocking the horizon-amgen deal will be worse for pharma than for biotech, says mizuho's jared holz
-
2:41
2022 looks like an execution year for the ev industry: oppenheimer analyst
-
7:03
market is in a 'healing process,' says oppenheimer strategist
-
4:22
alphabet is not a 'favored' name among investors right now, says oppenheimer's jason helfstein
-
4:36
we think alphabet is very well positioned right now, says oppenheimer's helfstein
-
3:33
jefferies' michael yee still likes amgen in the biotech sector
-
4:58
vital knowledge's adam crisafulli is bullish near term, but expects headwinds in the medium
-
3:29
oppenheimer's ari wald shares bullish sentiment on squarespace
-
5:12
structure therapeutics is a 'no-brainer takeout' target, says mizuho's jared holz
-
3:48
market pullback won't turn into bear market: oppenheimer
Clip.africa.com - Privacy-policy